# MissionIRNewsBreaks – Lantern Pharma Inc. (NASDAQ: LTRN) Advances Predictive Power in Cancer Drug Development

Lantern Pharma (NASDAQ: LTRN) recently unveiled a new artificial intelligence module designed to predict the effectiveness of cancer treatment combinations involving DNA-damaging agents (“DDAs”) and DNA damage response inhibitors (“DDRis”). “The technology is integrated into the company’s RADR(R) platform, which supports AI-guided drug development,” reads a recent article. “By embedding this technology into RADR(R), Lantern Pharma continues to position itself as a developer of data-driven approaches to oncology drug development. The module not only improves the chances of clinical success but also aligns with growing industry efforts to personalize cancer treatments based on molecular and genetic profiles.”

 To view the full article, visit https://ibn.fm/5maVc

 About Lantern Pharma Inc.

 Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. The company’s proprietary AI and machine learning platform, RADR(R), leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, Lantern has accelerated the development of its growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers. On average, Lantern’s newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $2.5 million per program.

 NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN

 About MissionIR

 MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

 MIR is where breaking news, insightful content and actionable information converge.

 For more information, please visit www.MissionIR.com

 Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

 MissionIRAustin, Texaswww.MissionIR.com512.354.7000 OfficeEditor@MissionIR.com

 MissionIR is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/mir/missionirnewsbreaks-lantern-pharma-inc-nasdaq-ltrn-advances-predictive-power-in-cancer-drug-development/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/lantern-pharma-unveils-ai-module-to-predict-cancer-treatment-success/4e7d5939fc1230b290399bdbf1672549) 

 



[Reddit Post](https://www.reddit.com/r/technology_press/comments/1n2lvks/lantern_pharma_unveils_ai_module_to_predict/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/258/28/tall0Ip0.webp)